Alnylam Pharma (Nasdaq: ALNY) has initiated its DISCOVERY trial, a screening study examining the prevalence of transthyretin (TTR) mutations in ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE